Search Results - Prajna Guha
- Showing 1 - 6 results of 6
-
1
Assessing the Future of Solid Tumor Immunotherapy by Prajna Guha, Kara R. Heatherton, Kyle P. O’Connell, Ian S. Alexander, Steven C. Katz
Published in Biomedicines (2022-03-01)Get full text
Article -
2
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models by Lauren Cournoyer, Yujia Liu, David B. Jaroch, Tom G. Hullinger, Bryan F. Cox, Steven C. Katz, Steven C. Katz, Jason LaPorte, Ilan B. Layman, Alizee Ballarin, Chandra C. Ghosh, Prajna Guha
Published in Frontiers in Oncology (2025-10-01)Get full text
Article -
3
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity by Louis F. Chai, John C. Hardaway, Kara R. Heatherton, Kyle P. O’Connell, Mikayla C. Lopes, Benjamin A. Rabinowitz, Chandra C. Ghosh, Prajna Guha, David Jaroch, Bryan F. Cox, Steven C. Katz
Published in Vaccines (2021-07-01)Get full text
Article -
4
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery by Mirela Stancu, Robert Knight, Jason Laporte, Prajna Guha, Steven C Katz, Jill E Slansky, Ashley E Moody, John C Hardaway, Ethan Prince, Kimberly R Jordan, Richard D Schulick, Abdul Saied, Vincent Armenio, Richard P Junghans
Published in Journal for ImmunoTherapy of Cancer (2020-10-01)Get full text
Article -
5
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myel... by Diwakar Davar, Yujia Liu, Jason Laporte, Prajna Guha, Steven C Katz, Chandra C Ghosh, Lauren Cournoyer, Alizee Ballarin, Ilan B Layman, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha
Published in Journal for ImmunoTherapy of Cancer (2024-07-01)Get full text
Article -
6
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial by David Geller, Ashley Moody, Richard Carvajal, Cara Haymaker, Sunil Reddy, Jose Lutzky, Shailender Bhatia, Diwakar Davar, Bartosz Chmielowski, Theresa Medina, Eric Wehrenberg-Klee, Marlana Orloff, Rahul Sheth, Sapna P Patel, Robert Knight, Jason Laporte, Prajna Guha, Bryan Cox, Steven Katz, Paula Novelli, Joshua D Kuban, Ann-Marie Hulstine, Kamaneh Montazeri, Shaheer A Khan, Lindsay Thornton, Anthony Lucci, Vanessa Sarli, Salyna Meas, Chandra C Ghosh
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article
